Are you Dr. Ridenhour?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 65 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1000 Breckenridge St
Ste 400
Owensboro, KY 42303Phone+1 270-688-3445Fax+1 270-688-3444
Summary
- Dr. Kevin Ridenhour, MD is an oncologist in Owensboro, Kentucky. He is currently licensed to practice medicine in Kentucky, Indiana, and Tennessee. He is affiliated with Owensboro Health Regional Hospital, Deaconess Midtown Hospital, and Memorial Hospital and Health Care Center.
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1994 - 1997
Brody School of Medicine at East Carolina UniversityClass of 1994
Certifications & Licensure
IN State Medical License 2022 - 2025
KY State Medical License 2010 - 2025
NC State Medical License 1996 - 2025
TN State Medical License 2004 - 2011
VA State Medical License 1997 - 2000- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Publications & Presentations
PubMed
- 26 citationsPhase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.Peter E. Clark, M. Craig Hall, Antonius A. Miller, Kevin P. Ridenhour, Diana Stindt
Urology. 2004-06-01
